Hung-Chun Yu

Hung-Chun Yu

Auto-generated profile, based on publicly available information

Hung-Chun Yu

Human Longevity Inc., San Diego, CA 92121, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TLTao Long
Tao Long
MHMichael Hicks
Michael Hicks
HYHung-Chun Yu
Hung-Chun Yu
WBWilliam H Biggs
William H Biggs
EKEwen F Kirkness
Ewen F Kirkness
Amalio TelentiAmalio Telenti
Amalio Telenti

26 February 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JIJulia di Iulio
Julia di Iulio
IBIstvan Bartha
Istvan Bartha
EWEmily H. M. Wong
Emily H. M. Wong
HYHung-Chun Yu
Hung-Chun Yu
VLVictor Lavrenko
Victor Lavrenko
Amalio TelentiAmalio Telenti
Amalio Telenti

1 April 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NSNaisha Shah
Naisha Shah
YHYing-Chen Claire Hou
Ying-Chen Claire Hou
HYHung-Chun Yu
Hung-Chun Yu
RSRachana Sainger
Rachana Sainger
CCC. Thomas Caskey
C. Thomas Caskey
Amalio TelentiAmalio Telenti
Amalio Telenti

24 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YHYing-Chen Claire Hou
Ying-Chen Claire Hou
HYHung-Chun Yu
Hung-Chun Yu
RMRick Martin
Rick Martin
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
NSNatalie M. Schenker-Ahmed
Natalie M. Schenker-Ahmed
CCC. Thomas Caskey
C. Thomas Caskey
Genome sequencing has established clinical utility for rare disease diagnosis. While increasing numbers of individuals have undergone elective genome sequencing, a comprehensive study surveying genome-wide disease-associated genes in adults with deep phenotyping has not been reported. Here we report the results of a 3-y precision medicine study with a goal to integrate whole-genome sequencing with deep phenotyping. A cohort of 1,190 adult participants (402 female [33.8%]; mean age, 54 y [range 20 to 89+]; 70.6% European) had whole-genome sequencing, and were deeply phenotyped using metabolomics, advanced imaging, and clinical laboratory tests in addition to family/medical history. Of 1,190 adults, 206 (17.3%) had at least 1 genetic variant with pathogenic (P) or likely pathogenic (LP) assessment that suggests a predisposition of genetic risk. A multidisciplinary clinical team reviewed all reportable findings for the assessment of genotype and phenotype associations, and 137 (11.5%) had genotype and phenotype associations. A high percentage of genotype and phenotype associations (>75%) was observed for dyslipidemia (n = 24), cardiomyopathy, arrhythmia, and other cardiac diseases (n = 42), and diabetes and endocrine diseases (n = 17). A lack of genotype and phenotype associations, a potential burden for patient care, was observed in 69 (5.8%) individuals with P/LP variants. Genomics and metabolomics associations identified 61 (5.1%) heterozygotes with phenotype manifestations affecting serum metabolite levels in amino acid, lipid and cofactor, and vitamin pathways. Our descriptive analysis provides results on the integration of whole-genome sequencing and deep phenotyping for clinical assessments in adults. Significance To understand the value and clinical impact of surveying genome-wide disease-causing genes and variants, we used a prospective cohort study design that enrolled volunteers who agreed to have their whole genome sequenced and to participate in deep phenotyping using clinical laboratory tests, metabolomics technologies, and advanced noninvasive imaging. The genomic results are integrated with the phenotype results. Approximately 1 in 6 adult individuals (17.3%) had genetic findings and, when integrated with deep phenotyping data, including family/medical histories with genetic findings, 1 in 9 (11.5%) had genotype and phenotype associations. Genomics and metabolomics association analysis revealed 5.1% of heterozygotes with phenotype manifestations affecting serum metabolite levels. We report observations from our study in which health outcomes and benefits were not measured.

1 September 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HYHung-Chun Yu
Hung-Chun Yu
JSJennifer L. Sloan
Jennifer L. Sloan
GSGunter Scharer
Gunter Scharer
ABAlison Brebner
Alison Brebner
AQAnita M Quintana
Anita M Quintana
TSTamim H. Shaikh
Tamim H. Shaikh

1 April 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FVF.-Nora Vögtle
F.-Nora Vögtle
BBBjörn Brändl
Björn Brändl
ALAustin Larson
Austin Larson
MPManuela Pendziwiat
Manuela Pendziwiat
MFMarisa W. Friederich
Marisa W. Friederich
IHIngo Helbig
Ingo Helbig